Lab
Medical Foundation, INC.
Medical Foundation, INC. was paid $4.20M by Medicaid between Jan 2018 and Dec 2024, across 139 billing codes. Its largest line is 87591, Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe — 10.0% of everything it billed.
33Billing provider infoMEDICAL FOUNDATION, INC.
MERIDIAN, MS 39301
MERIDIAN, MS 39301
33aNPI1467857102assigned 10/23/2014
33bProvider typeClinical Medical Laboratory
28Total paid$4.20M
24GClaims392,175
24DCodes billed139
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Mississippi
Rank by total paid#3 of 35
Median peer was paid$136K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KENNEDY, DON controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,831 | $204K | |
| 2019 | 39,738 | $501K | |
| 2020 | 44,740 | $514K | |
| 2021 | 65,303 | $699K | |
| 2022 | 87,220 | $885K | |
| 2023 | 78,354 | $778K | |
| 2024incomplete | 56,989 | $625K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 10.0% | 17,247 | 15,032 | $420K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 9.4% | 17,295 | 15,084 | $396K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.5% | 39,042 | 33,968 | $232K |
| 80053 | Comprehensive metabolic panel | 4.6% | 26,724 | 23,682 | $195K |
| 80061 | Lipid panel | 4.3% | 20,127 | 17,864 | $182K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.7% | 13,743 | 12,103 | $157K |
| 87480 | 3.7% | 11,498 | 9,846 | $153K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.6% | 9,385 | 8,196 | $152K |
| 87660 | 3.6% | 11,415 | 9,812 | $152K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.6% | 8,273 | 7,166 | $149K |
| 87510 | 3.3% | 11,433 | 9,778 | $138K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.1% | 5,362 | 3,814 | $130K |
127 more codes
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.8% | 1,609 | $118K |
| 86780 | 2.6% | 11,262 | $108K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.3% | 3,098 | $96K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.1% | 14,538 | $90K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 12,778 | $73K |
| 80050 | General health panel | 1.7% | 2,684 | $70K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 1,772 | $66K |
| 87653 | 1.5% | 2,775 | $65K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.4% | 2,432 | $59K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.2% | 2,808 | $51K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 7,831 | $50K |
| 80074 | <1% | 1,816 | $41K | |
| 82607 | <1% | 4,101 | $41K | |
| 87077 | <1% | 5,803 | $37K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 784 | $37K |
| 86696 | <1% | 2,781 | $36K | |
| 86803 | <1% | 3,786 | $36K | |
| 83655 | <1% | 4,315 | $34K | |
| 86762 | <1% | 3,178 | $34K | |
| 84439 | <1% | 5,788 | $34K | |
| 87186 | <1% | 5,053 | $33K | |
| 87340 | <1% | 4,289 | $33K | |
| 84702 | <1% | 3,505 | $30K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,825 | $29K |
| 86695 | <1% | 2,794 | $28K | |
| 82746 | <1% | 2,565 | $23K | |
| 86850 | <1% | 3,525 | $21K | |
| 86694 | <1% | 1,902 | $20K | |
| 82043 | <1% | 4,628 | $18K | |
| 82728 | <1% | 2,073 | $18K | |
| 82570 | <1% | 5,090 | $18K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,145 | $17K |
| 83550 | <1% | 2,391 | $15K | |
| 87428 | <1% | 356 | $15K | |
| 80081 | <1% | 235 | $13K | |
| 81001 | <1% | 5,586 | $13K | |
| 87070 | <1% | 1,945 | $13K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 314 | $13K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 226 | $12K |
| 83540 | <1% | 2,628 | $12K | |
| 82950 | <1% | 2,893 | $10K | |
| 87081 | <1% | 1,819 | $10K | |
| 86703 | <1% | 948 | $10K | |
| 85660 | <1% | 2,423 | $9K | |
| 83880 | <1% | 378 | $8K | |
| 80076 | <1% | 1,341 | $8K | |
| 87088 | <1% | 1,188 | $7K | |
| 86038 | <1% | 825 | $7K | |
| 84703 | <1% | 1,280 | $7K | |
| 86900 | <1% | 3,273 | $6K | |
| 86901 | <1% | 3,219 | $6K | |
| 83001 | <1% | 356 | $5K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 432 | $5K |
| 86140 | <1% | 1,379 | $5K | |
| 81003 | <1% | 1,976 | $4K | |
| 87210 | <1% | 1,231 | $4K | |
| 80305 | <1% | 682 | $4K | |
| 85651 | <1% | 1,445 | $4K | |
| 84550 | <1% | 1,088 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 178 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 285 | $3K |
| 83735 | <1% | 801 | $3K | |
| 84403 | <1% | 212 | $3K | |
| 86003 | <1% | 219 | $3K | |
| 82947 | <1% | 1,011 | $3K | |
| 86706 | <1% | 390 | $3K | |
| 87506 | <1% | 15 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 532 | $2K |
| 80164 | <1% | 233 | $2K | |
| 83690 | <1% | 479 | $2K | |
| 83002 | <1% | 152 | $2K | |
| 83970 | <1% | 55 | $2K | |
| 85610 | <1% | 632 | $1K | |
| 85018 | <1% | 723 | $1K | |
| 86787 | <1% | 133 | $1K | |
| 82248 | <1% | 275 | $1K | |
| 84144 | <1% | 76 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 86 | $1K |
| 86592 | <1% | 345 | $980.16 | |
| 84146 | <1% | 69 | $855.30 | |
| 84153 | <1% | 61 | $852.54 | |
| 82150 | <1% | 196 | $842.35 | |
| 82677 | <1% | 54 | $818.33 | |
| 84156 | <1% | 357 | $774.96 | |
| 87807 | <1% | 79 | $683.65 | |
| 81025 | <1% | 123 | $630.78 | |
| 85014 | <1% | 301 | $554.72 | |
| 84481 | <1% | 43 | $527.32 | |
| 86336 | <1% | 54 | $511.48 | |
| 82105 | <1% | 41 | $425.71 | |
| 86431 | <1% | 99 | $366.09 | |
| 84436 | <1% | 87 | $348.07 | |
| 87529 | <1% | 13 | $315.80 | |
| 82785 | <1% | 72 | $304.69 | |
| 84478 | <1% | 87 | $258.89 | |
| 82550 | <1% | 66 | $203.65 | |
| 86430 | <1% | 45 | $203.10 | |
| 85730 | <1% | 53 | $195.06 | |
| 80185 | <1% | 16 | $188.94 | |
| 86376 | <1% | 24 | $176.20 | |
| 82784 | <1% | 19 | $166.39 | |
| 84460 | <1% | 43 | $152.66 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 27 | $80.93 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 19 | $64.73 |
| 85046 | <1% | 12 | $63.33 | |
| 82565 | <1% | 15 | $52.10 | |
| 80069 | <1% | 14 | $27.15 | |
| 93000 | <1% | 20 | $26.34 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13 | $21.05 |
| 87390 | <1% | 13 | $20.57 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 90 | $5.68 |
| 71045 | Radiologic examination, chest; single view | <1% | 63 | $2.64 |
| 80373 | 0% | 14 | $0.00 | |
| 80346 | 0% | 14 | $0.00 | |
| 80365 | 0% | 13 | $0.00 | |
| 80348 | 0% | 14 | $0.00 | |
| 71046 | Radiologic examination, chest; 2 views | 0% | 42 | $0.00 |
| 80361 | 0% | 13 | $0.00 | |
| 80372 | 0% | 27 | $0.00 | |
| 80354 | 0% | 13 | $0.00 | |
| 80356 | 0% | 13 | $0.00 | |
| 3044F | 0% | 86 | $0.00 | |
| 80358 | 0% | 14 | $0.00 | |
| 80324 | 0% | 13 | $0.00 | |
| 80353 | 0% | 13 | $0.00 | |
| 81511 | 0% | 18 | $0.00 | |
| 80349 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKENNEDY, DON (REGIONAL CEO)
| Provider | Location | Paid |
|---|---|---|
| Rush Medical Foundation | Meridian, MS | $29.41M |
| Laird Hospital, INC. | Union, MS | $7.23M |
| Laird Hospital, INC. | Meridian, MS | $5.90M |
| Laird Hospital, INC | Meridian, MS | $5.27M |
| Rush Medical Foundation | Quitman, MS | $4.69M |
| Kemper, Cah, INC | Livingston, AL | $4.50M |
| Kemper Cah, INC. | De Kalb, MS | $4.06M |
| Scott Regional Medical Center, INC. | Morton, MS | $3.77M |
| Kemper Cah, INC | Meridian, MS | $3.39M |
| Rush Hospital/Butler, INC | Butler, AL | $1.94M |
| Medical Foundation, INC. | Meridian, MS | $1.82M |
| The Medical Store, INC. | Meridian, MS | $1.66M |
| Rush Medical Foundation | Meridian, MS | $1.61M |
| Medical Foundation, INC. | Meridian, MS | $1.37M |
| Laird Hospital, INC. | Union, MS | $1.31M |
| Medical Foundation, INC. | Meridian, MS | $1.27M |
| Scott Regional Medical Center, INC. | Morton, MS | $1.21M |
| Rush Medical Foundation | Quitman, MS | $978K |
| Kemper Cah, INC | Meridian, MS | $910K |
| Laird Hospital, INC. | Philadelphia, MS | $898K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.